Le cancer de l'ovaire est la première cause de décès par cancer gynécologique. Cette thèse avait pour objectif la prospection de nouvelles solutions thérapeutiques fondées sur la délivrance prolongée d'agents anti tumoraux à l'aide de systèmes macromoléculaires de synthèse. L'un des obstacles majeurs était la disposition d'un modèle de tumeur pertinent chez l'animal. Après un examen bibliographique des connaissances acquises, le deuxième chapitre examine le potentiel d'un panel de xénogreffes dérivées de tumeurs ovariennes humaines directement greffées chez la souris immunodéprimée. Il est montré que les principales caractéristiques phénotypiques et moléculaires des tumeurs originales sont maintenues au niveau des greffes. Les résultats traduisent la présence d'une hétérogénéité intra-tumorale et d'une oligoclonalité au niveau des tumeurs primaires. L'ensemble confirme l'importance du choix du modèle tumoral pour l'évaluation de nouveaux traitements et l'étude des mécanismes aboutissant aux rechutes de la maladie et au développement d'une chimiorésistance. Un troisième chapitre traite l'exemple d'un système de délivrance prolongée fondé sur le couplage d'un agent antitumoral modèle, la doxorubicine, associé de diverses manières à un vecteur macromoléculaire biorésorbable, le poly(L-lysine citramide). Le premier conjugué obtenu par couplage direct sur le vecteur étant trop stable, divers systèmes ont été conçus pour obtenir la libération souhaitée. L'utilisation d'un bras espaceur clivable de type ester-hydrazone a fourni le meilleur résultat. Pour pallier la complexité de ces conjugués, une stratégie innovante fondée sur le piégeage de la doxorubicine dans une gélatine artificielle à base de poly(N-acryloyl glycinamide) est prospectée qui devrait permettre l'utilisation simultanée de plusieurs principes actifs piégés temporairement par voie physique dans un gel adhésif et fournir des solutions mieux adaptées aux contraintes cliniques des traitements intrapéritonéaux. / Ovarian carcinoma is the most lethal gynecologic malignancy. The aim of this PhD thesis was to develop new therapeutic approaches based on novel synthetic macromolecular drug delivery systems for intraperitoneal chemotherapy. These objectives were limited by the requirement of reliable tumor models for experimental studies. After a concise review of knowledge published in the literature, the potential interest of the establishment of a collection of tumor grafts derived from samples of human tumors is examined in a second chapter. Data show that the major phenotypic and genotypic features of the original tumors are maintained in the xenografts. They also confirm the importance of this tumor model to test new drugs and to analyze intratumoral heterogeneity and oligoclonality in primary ovarian carcinoma. The collection will be also helpful to study the mechanisms leading to disease recurrences and resistance to chemotherapies. An example of drug delivery system based on the different associations of a model chemotherapeutic drug (doxorubicin) with a bioresorbable macromolecular vector, namely poly(L-lysine citramide), is addressed in a third chapter. Direct amid linkage in the first conjugate was too stable with respect to antitumoral cytotoxicity desired after in vivo administration and different systems were generated subsequently to increase drug release in tumor deposits. The best results were obtained with a hydrazone cleavable spacer containing an ester group. To overcome the complexity of these conjugates, a novel strategy based on doxorubicin entrapment in a synthetic gelatin made of (poly(N-acryloyl glycinamide) is developed. This strategy should allow physical temporary entrapment of different drug molecules in a adhesive gel and could provide new solutions to the therapeutic challenges of intraperitoneal administration.

Les lymphocytes T ?d seraient des effecteurs essentiels dans la réponse immunitaire aux stress induits notamment par les infections et la tumorigénèse. Plusieurs arguments dont leur localisation intra-épithéliale mais aussi leurs capacités effectrices multiples et rapides les caractérisent comme des acteurs primordiaux dans l’immunité anti-tumorale. Mon projet de thèse consistait à examiner le potentiel anti-tumoral des lymphocytes T ?d humains, Vd2 négatifs (neg), dans un contexte in vivo, grâce à l’utilisation d’un modèle murin. Des études antérieures menées au laboratoire démontraient une expansion de lymphocytes T Vd2neg dans la circulation sanguine de transplantés rénaux développant une infection à cytomégalovirus (CMV). Des clones T Vd2neg, isolés de ces patients, présentaient une forte réactivité in vitro contre des cellules infectées par le CMV mais aussi contre des cellules tumorales notamment d’origine colique (comme la lignée HT29). Un ligand commun induit par l’infection à CMV et la transformation tumorale, reconnu par les clones T Vd2neg serait à l’origine de cette double réactivité. La première partie de mon projet s’est concentrée sur l’étude du potentiel anti-tumoral de ces clones T Vd2neg in vivo, qui comprenait leur capacité à atteindre des cellules tumorales d’origines coliques (HT29) et à les lyser. Dans un modèle de xénogreffe dans des souris immunodéficientes, nous avons démontré que les clones TVd2neg, injectés dans le péritoine (i.p) pouvaient retarder la croissance de tumeurs solides HT29 sous-cutanées. D’après nos résultats, cette inhibition du développement tumoral proviendrait d’une action précoce et spécifique des cellules T Vd2neg et impliquerait le récepteur à chimiokine CCR3. Nos données suggèrent donc que des lymphocytes T Vd2neg, réactifs contre le CMV, pourraient migrer in vivo jusqu’au site d’injection des cellules tumorales et inhiber la croissance de la tumeur probablement grâce à leur acticité cytolytique. La deuxième partie de mon projet de thèse proposait d’approfondir l’étude du rôle des lymphocytes T Vd2neg contre les tumeurs coliques. Ainsi nous avons testé, in vivo, l’implication de lymphocytes T Vd1+ humains, une population représentative des épithéliums intestinaux, dans le cancer métastatique colorectal (CMC). Nous avons développé un modèle d’implantation orthotopique de cellules tumorales HT29 dans des souris immunodéficientes, qui mime le développement du CMC chez l’homme. Des tumeurs primaires intra-caecales et des métastases pulmonaires et hépatiques se développent chez les souris. De plus, nous avons pu suivre leur croissance grâce à l’introduction de la luciférase dans les HT29 et à une technique d’imagerie in vivo en bioluminescence. Nos résultats montrent qu’un traitement continu des souris par des injections de lignée T Vd1+ en i.p inhibe le développement des tumeurs primaires et retarde l’apparition des métastases à distance. Ces données soutiennent l’implication des lymphocytes T Vd2neg dans le contrôle des CMC. De façon intéressante, elles mettent en avant une implication anti-métastatique des cellules T Vd2neg. L’ensemble de nos travaux souligne le rôle des cellules T Vd2neg dans la réponse immunitaire contre les cancers colorectaux et étaye leur potentiel d’action lors de la progression des tumeurs vers des métastases, ouvrant ainsi des perspectives pour l’utilisation de ces cellules dans les thérapies des CMC. / Gamma delta (?d) T lymphocytes contribute to host immune competence uniquely especially during stress immune responses to infections and tumors. Because ?d T cells colonize epithelial surfaces, where they can exert rapid and pleiotropic effector functions, they are critical protagonists in anti-cancer response. During my Phd project we explored the anti-tumor potential of Vd2 negatives (neg) ?d T lymphocytes, in vivo using a mouse xenograft tumor model. A few years ago, studies in our laboratory showed an increase of peripheral blood Vd2neg ?d T lymphocytes in allograft recipients infected by cytomegalovirus (CMV). Interestingly, Vd2neg ?d T clones isolated from these patients showed a cytotoxic activity against CMV infected fibroblast in vitro. Moreover, they were able to kill colon cancer cells (HT29) in vitro, in contrast to normal epithelial cells. Cancer cell- as well as CMV infected cell- killing involved T cell receptor (TCR) engagement, independently of major histocompatibility complex (CMH) recognition, probably with a common ligand. The first part of my Phd project was undertaken to evaluate the in vivo tumor reactivity of anti-CMV Vd2neg clones, including their ability to inhibit tumor growth as well as their migratory potential toward colon cancer cells. In immunodeficient mice, we showed that systemic intraperitoneal (i.p) injections with human Vd2neg clones inhibited the growth of HT29 hypodermal tumors xenografts. Furthermore, our results demonstrated that Vd2neg T cells had an early and specific anti-tumor effect, and that such activity could be hampered in vivo using an anti-CCR3 antibody. Our study suggest that Vd2neg T cells with an anti-viral potential are able to reach a tumor site in vivo, and inhibit tumoral growth exercising a cytolytic activity. The second part of my Phd project proposed to get further insights on the role of Vd2neg T cells in the immune surveillance against colon cancer. To this aim, we tested, the involvement of human Vd1+ T lymphocytes, a substantial fraction of T cells in intestinal epithelia, in limiting tumor spread in vivo, using a mouse model of colorectal carcinoma (CRC). We sat up a physiological mouse model of CRC by orthotopic microinjection of HT29 colon cell, which mimics the natural history of human CRC. Indeed, primary colic tumors and pulmonary and hepatic distant metastases grew in mice. Furthermore, bioluminescence imaging was used to follow the outcome of luciferase expressing cancer cells. We showed that systemic treatment with human Vd1+ T lymphocytes could inhibit the growth of intracaecal HT29 tumors and led a substantial reduction of distant metastases. Our results are the first arguing for a crucial role of ?d T cells against CRC, specially in preventing the dissemination of colon cancer cells. Taken together, our results underline the role of of ?d T cells in theimmune response against colorectal cancer. Our findings put forward Vd2neg T cells as attractive candidates for novel anti-tumor immunotherapy protocols.

O adenocarcinoma ductal pancreático (PDAC, pancreatic ductal adenocarcinoma), o tipo mais prevalente de câncer do pâncreas, é uma neoplasia extremamente agressiva e com elevado índice de letalidade. Há uma necessidade premente de identificação de vulnerabilidades no PDAC que possam ser exploradas como alvos terapêuticos, e a utilização de modelos pré-clínicos que recapitulem a complexidade biológica e heterogeneidade clínica da doença é um aspecto central para a realização dessa tarefa. Os xenotransplantes de tecido tumoral derivado de pacientes (PDX, patient-derived tumor tissue xenografts), realizados em camundongos imunodeficientes, replicam com grande similaridade as principais características do tumor original e, assim, constituem uma ferramenta valiosa para o teste de drogas e estudos funcionais. Neste trabalho, 17 amostras cirúrgicas de PDAC humano foram implantadas subcutaneamente em camundongos nude atímicos. Sete tumores (41%) foram enxertados com sucesso e têm sido mantidos em sucessivas gerações de animais receptores. O exame histológico de seis desses xenoenxertos identificou características morfológicas compatíveis com os padrões reconhecidos no PDAC humano, assim como uma consistente similaridade de seu status de diferenciação histológica em relação aos perfis verificados nos tumoresoriginais. O cultivo in vitro de células derivadas de um dos xenotumores resultou em uma nova linhagem de câncer de pâncreas, com morfologia e cinética de crescimento comparáveis às de outras linhagens celulares de câncer pancreático. O potencial tumorigênico dessa nova linhagem foi validado in vivo, com uma consistente formação de tumores após inoculação em camundongos nude. A fim de aproveitar esse recurso para a investigação de potenciais alvos terapêuticos no PDAC, um rastreamento de vulnerabilidades moleculares foi realizado por meio de silenciamento gênico em larga-escala com RNA de interferência (RNAi). Uma biblioteca lentiviral de 4492 shRNAs (short hairpin RNAs), alvejando cerca de 350 genes envolvidos na regulação epigenética, foi empregada para a triagem de genes de suscetibilidade nas células derivadas de PDX, e em outras cinco linhagens tumorais pancreáticas (AsPC-1, BxPC-3, Capan-1, MIA PaCa-2 e PANC-1). Inicialmente, foi realizada uma série de experimentos preliminares, visando à amplificação e controle de qualidade da biblioteca de silenciamento, à produção de vetores lentivirais e à padronização das condições experimentais para a transdução e seleção das células-alvo. Apenas três das linhagens avaliadas (AsPC-1, MIA PaCa-2 e PANC-1) mostraram-se permissíveis à transdução pelos vetores lentivirais, e foram assim utilizadas no screening de alvos epigenéticos. A análise dos dados obtidos nesse ensaio está em curso e os resultados serão utilizados para a definição de potenciais alvos candidatos. Em conclusão, recursos valiosos para apoiar a pesquisa sobre o câncer de pâncreas foram desenvolvidos. A coleção de PDXs estabelecida, bem como a linhagem celular recém-derivada, constituem uma fonte permanente e estável de células de PDAC para análises moleculares e estudos funcionais que busquem elucidar aspectos da doença ainda pouco compreendidos. Adicionalmente, os reagentes gerados e a expertise adquirida com os ensaiosrealizados com a biblioteca de shRNAs contra alvos epigenéticos serão de grande utilidade em futuras investigações para identificar genes com funções importantes na manutenção do fenótipo tumoral, e consequentemente com potencial para serem explorados terapeuticamente. / Pancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer, is a highly aggressive and lethal neoplasm. There is a pressing need to identify vulnerabilities in PDAC suited to be exploited as therapeutic targets, and the use of preclinical models recapitulating the biological complexity and clinical heterogeneity of the disease is central to this task. Patient-derived tumor tissue xenografts (PDX), established in immunodeficient mice, replicate with great similarity the main characteristics of the original tumor and thus constitute a valuable tool for drug testing and functional studies. In this work, 17 surgical samples of human PDAC were implanted subcutaneously in athymic nude mice. Seven tumors (41%) were successfully grafted and have been maintained through successive generations of recipient animals. Histological examination of six of these xenografts identified morphological characteristics compatible with the recognized patterns of human PDAC, as well as a consistent similarity of their histological differentiation status in relation to the profiles verified in the original tumors. In vitro culture of cells derived from one of these xenografts resulted in a new pancreatic cancer cell line, with morphology and growth kinetics comparable to those of other pancreatic tumor cells. The tumorigenic potential of this freshly derived cell line was validated in vivo, with a consistent tumor formation following inoculation into nude mice. To take advantage ofthis resource to investigate potential therapeutic targets in PDAC, a screening of molecular vulnerabilities was performed through large-scale gene silencing with RNA interference (RNAi). A lentiviral library containing 4492 short hairpin RNAs (shRNAs), targeting about 350 genes involved in epigenetic regulation, was employed for the search of susceptibility genes in the PDX-derived cells and in other five pancreatic tumor cell lines (AsPC-1, BxPC -3, Capan-1, MIA PaCa-2 and PANC-1). Initially, a series of preliminary experiments were carried out aiming at the amplification and quality control of the silencing library, production of lentiviral vectors and adjustment of the experimental conditions for transduction and selection of the target cells. Only three of the cell lines evaluated (AsPC-1, MIA PaCa-2 and PANC-1) were permissible for transduction by the lentiviral vectors, and were accordingly used in the screening of epigenetic targets. The analysis of data obtained in this trial is ongoing and the results will be used for definition of potential candidate targets. In conclusion, valuable resources to support research on pancreatic cancer have been developed. The established collection of PDXs as well as the newly derived cell line constitutes a permanent and stable source of PDAC cells for molecular analyzes and functional studies seeking to elucidate aspects of this disease that are still poorly understood. Additionally, both the reagents generated and the expertise gained from the RNAi assay against epigenetic targets will have inordinate usefulness in future investigations to identify genes with major functions in maintaining the malignant phenotype, and consequently with the potential to be exploited therapeutically.

La P-glycoprotéine (P-gp) est une protéine transmembranaire de la famille des ATP binding cassette transporteurs. Elle est impliquée dans l’efflux du milieu intracellulaire vers le milieu extracellulaire d’une grande variété de médicaments anticancéreux. Elle peut être responsable de la diminution de la biodisponibilité orale et de la concentration intra-tumorale des médicaments qui en sont substrats. Elle peut notamment être surexprimée par les cellules cancéreuses des adénocarcinomes du colon naïfs de tout traitement, suggérant une résistance naturelle de cette tumeur et également après une chimiothérapie. Notre premier travail in vivo a documenté le caractère substrat de la P-gp de l’evérolimus, inhibiteur de mTOR indiqué dans divers cancers (rein, tumeurs neuroendocrines d’oringine pancréatique et sein), jusqu’à maintenant uniquement étudié dans des modèles in vitro. Une augmentation significative de l’AUC de l’evérolimus administré par voie orale est observée chez des souris mdr1a-/b- comparées à des souris mdr1a+/1b+. Une amélioration significative de la biodisponibilité orale de l’evérolimus est aussi notée chez des souris prétraitées par le lapatinib (Tyverb®), inhibiteur des tyrosines kinases (EGFR et HER2) indiqué dans le cancer du sein, par rapport aux souris ayant reçu l’evérolimus seul. Ce résultat est accompagné d’une inhibition de l’expression de la P-gp intestinale par le lapatinib mesurée par la technique de Western Blot. Enfin, une étude préclinique menée chez des souris porteuses d’une xénogreffe colorectale mutée KRAS montre une activité anti-tumorale certaine des deux médicaments utilisés seuls et en schéma séquentiel. Notre seconde étude a montré pour la première fois que le cétuximab (Erbitux®), anticorps anti-EGFR, inhibe la fonctionnalité de la P-gp dans deux lignées cellulaires surexprimant la P-gp (les cellules IGROV-1 et les HEK P-gp) indépendamment de leur statut EGFR et entraîne chez des souris porteuses d’une xénogreffe colorectale une augmentation significative de la biodisponibilité orale et de la concentration intra-tumorale du SN-38, métabolite actif de l’irinotécan (Campto®) administré par voie orale. Le cétuximab étant prescrit en association avec l’irinotécan chez des patients atteints d’un cancer colorectal métastasé, initialement réfractaire à l’irinotécan, ces résultats pourraient en partie expliquer la réversion de la résistance à l’irinotécan par le cétuximab par une inhibition de l’efflux de la P-gp. Grâce à l’étude de deux associations de médicaments «lapatinib-evérolimus» et «cétuximab-irinotécan», nous avons démontré l’intérêt de l’étude de l’inhibition de la P-gp avec les traitements les plus récents, notamment son rôle dans l’amélioration de la biodisponibilité orale de chimiothérapies utilisées par voie orale. / P-glycoprotein (P-gp) is a membrane transporter and belongs to the ATP-binding cassette (ABC) transporter super family. P-gp decreases oral bioavailability of substrate drugs and can cause multidrug resistance in tumor cells by decreasing intracellular drug levels. P-gp is overexpressed in colorectal carcinoma naturally resistant to chemotherapy. The aim of our first study was to document the in vivo transport of everolimus (Afinitor®), a mTOR inhibitor, by P-gp. A significant increase of everolimus oral bioavaibility was observed in mdr1a-/1b- mice compared to the wild type. In addition, a significant increase of everolimus oral bioavaibility was showed in mice that received a lapatinib pre-treatment (a dual EGFR/HER2 tyrosine kinase inhibitor) compared to mice that received everolimus alone. These results were accompanied by a significant decrease of P-gp expression in duodenum segment in lapatinib pre-treated group as compared to control group. Finally, each drug given alone or in association showed a major antitumor activity in a xenograft model of human colorectal carcinoma with KRAS mutation. Our second study showed for the first time that cetuximab (Erbitux®), a monoclonal antibody directed towards EGFR, inhibits P-gp functionality in two cell lines overexpressing P-gp (IGROV-1 and HEK P-gp cells) independently of EGFR status and leads to significant increases of oral bioavailability and intratumoral concentration of SN-38, the active metabolite of irinotecan (Campto®) in mice bearing colorectal carcinoma xenograft. Cetuximab is used in combination with irinotecan in patients with metastatic colorectal cancer, initially refractory to irinotecan, our results may partly explain the reversion of resistance to irinotecan by inhibiting P-gp efflux by cetuximab. In conclusion, our results showed the interest to study the effect of recent anticancerous drugs on P-gp, including their ability to improve oral bioavailability of oral chemotherapy used.

Clinical management of esophageal adenocarcinoma (EAC) relies on radiation therapy, yet radioresistance is a pervasive challenge in this disease. The mechanisms of EAC radioresistance remain largely unknown due to a paucity of validated preclinical models. The present studies report on the development of seven primary xenograft models established from patient tumours. These models are used to interrogate the range of radiosensitivities and mechanisms of radioresistance in EAC tumours. We found that radiation enriches the tumour-initiating cell population in two xenograft lines tested. Furthermore, three tested xenograft lines respond to irradiation by upregulating Hedgehog transcripts, a pathway involved in stem cell maintenance and proliferation. Upregulation occurs in autocrine and paracrine patterns simultaneously, suggesting that Hedgehog signalling may have a complex role in the radioresponse of EAC tumours. These findings suggest that inhibiting stem cell pathways in combination with radiotherapy may have an important role in the clinical management of EAC.

Des progrès considérables ont été faits dans le domaine de la xénotransplantation ces dernières années, menant à des essais cliniques controversés impliquant des enfants au Mexique. Des risques sont associés à la xénotransplantation (la transplantation à l'être humain d'organes, de tissus ou de cellules provenant de l'animal) pour le receveur mais aussi pour le public en général. L'objectif de ce mémoire consiste à évaluer l'applicabilité des lois actuelles à la xénotransplantation pour déterminer la protection offerte par cet encadrement juridique. Pour identifier les lois possiblement applicables à la xénotransplantation, nous l'avons divisée en trois périodes: avant la chirurgie, pendant la xénotransplantation et celle post-intervention. Pour chacune de ces périodes, nous avons reconnu quatre groupes de personnes susceptibles d'être touchées par la réalisation de xénotransplantations; les receveurs, leurs proches, l'équipe médicale et finalement, la population en général. Ayant à l'esprit ces paramètres, nous avons vérifié si la loi à l'étude pouvait être applicable à la xénotransplantation en considérant les définitions fournies et son champ d'application. Par exemple, nous avons examiné si le xénogreffon (cellules, tissus ou organes) pouvait se qualifier de drogue ou d'instrument médical selon la Loi sur les aliments et drogues. Une étude de droit comparé est présentée entre les lois canadiennes et celles des États-Unis, de la France et du Royaume-Uni. Nous concluons à la nécessité d'une harmonisation tant au niveau national qu'au niveau international. / Recent advances in transplantation have reached the point where it may be possible to transplant an organ, tissue or ceIl from an animal to a human. Certain potential risks, for the beneficiary and to public health are associated with this procedure, which is referred to as xenotransplantation. The purpose of this study is to evaluate the applicability of current legislation to the possible risks to public health posed by xenotransplantation. In investigating this potential of existing legislation, the xenotransplantation process was divided into three periods : before the surgery, during the xenotransplantation and finaIly, the post-intervention period. For each period, we identified which legislation could apply to the beneficiaries of the xenotransplantation, their relatives, the medical team or the public in general. Then, we verified if that legislation could be applicable to xenotransplantation by looking at the definitions and its field of application. For example, whether the xenograft (ceIls, tissus or organs) could be a drug or a medical instrument under the Canadian Food and Drug Act was considered. The legislation examined include, but are not limited to, those that usuaIly apply to clinical trials, transportation of dangerous goods, working conditions or quarantine. This analysis illustrates the variety of possible legal characterizations of the xenograft. A comparison between Canadian legislation and those of the United States, France and United Kingdom is presented. It is concluded that there is a need to harmonize regulations at both national and intemationallevels. / "Mémoire présenté à la Faculté des études supérieures en vue de l'obtention du grade de Maître en droit (LL.M.)"

Clinical management of esophageal adenocarcinoma (EAC) relies on radiation therapy, yet radioresistance is a pervasive challenge in this disease. The mechanisms of EAC radioresistance remain largely unknown due to a paucity of validated preclinical models. The present studies report on the development of seven primary xenograft models established from patient tumours. These models are used to interrogate the range of radiosensitivities and mechanisms of radioresistance in EAC tumours. We found that radiation enriches the tumour-initiating cell population in two xenograft lines tested. Furthermore, three tested xenograft lines respond to irradiation by upregulating Hedgehog transcripts, a pathway involved in stem cell maintenance and proliferation. Upregulation occurs in autocrine and paracrine patterns simultaneously, suggesting that Hedgehog signalling may have a complex role in the radioresponse of EAC tumours. These findings suggest that inhibiting stem cell pathways in combination with radiotherapy may have an important role in the clinical management of EAC.

A artroplastia é, em última análise, a opção final para o tratamento da osteoartrose. Com o aumento do número de indicações deste procedimento, a troca (artroplastia total de quadril de revisão – ATQR) dos componentes também passou a ser mais frequente. Os defeitos ósseos ou falhas ósseas são problemas que podem ser encontrados quando se realiza uma ATQR e, eles devem ser reparados, ou seja, o quadril do paciente a receber outra prótese necessita ser reconstruído. Para isto a grande maioria das técnicas empregadas requer o uso de enxerto ósseo e, devido a este motivo este tecido tem se tornado um dos tecidos mais transplantados na atualidade. Porém a demanda para utilização dos enxertos, na maioria provenientes de bancos de tecidos ósseos, tem aumentado, mas o suprimento é insuficiente. Portanto faz-se necessário a busca por novas tecnologias e alternativas aos bancos de tecidos. O enxerto bovino liofilizado (EBL) é uma destas opções, sua produção em livre demanda suas características físicas e químicas semelhantes ao osso humano e sua boa repercussão clínico-radiológica o torna uma alternativa viável. Este estudo tem o objetivo de verificar e quantificar a neoformação óssea com o uso do EBL pelo uso da avaliação histológica. Realizou-se um estudo de casos de Julho de 2000 a Abril de 2013 no Hospital de Clínicas de Porto Alegre (HCPA), onde se incluíram sujeitos que foram submetidos a uma cirurgia prévia cirurgia de ATQR onde foi utilizado o EBL os quais internaram posteriormente para uma segunda cirurgia de ATQR não relacionada a falha do enxerto e sim a falha da prótese. Nesta segunda cirurgia realizou-se a biópsia óssea. Quatorze sujeitos foram analisados, sendo 64,3% do sexo feminino. A média de idade dos pacientes foi 52,36±18,55. Neoformação óssea estava presente em 85,7% dos sujeitos, e constituiu 61,79% da área total de matriz óssea. O diagnóstico de absorção do EBL estava presente em 12 sujeitos. Uma forte correlação de proporção inversa foi constatada pelo teste de Pearson entre a porcentagem de osso neoformado e a porcentagem de EBL na área total de matriz óssea (p=0,001). Nenhuma resposta inflamatória foi encontrada. Concluiu-se que houve neoformação óssea adequada na grande maioria dos casos sendo o EBL uma boa estrutura osteocondutora, podendo ser considerado uma alternativa aos outros enxertos ósseos no tratamento das falhas ósseas. / Arthroplasty is, ultimately, the final option for the treatment of osteoarthritis. With the increasing number of indications of this procedure, the exchange (total hip arthroplasty revision surgery- THARS) also became more frequent. The bone defects are problems that can be encountered when conducting a THARS and this defect must be repaired, in other words, the patient's hip needs to be rebuilt before receive a new prosthesis. Most of techniques used to rebuild requires the use of bone graft, and because of this reason, this tissue has become one of the most transplanted tissues today. However the demand for the use of grafts, mostly from bone tissue banks, has increased, but the supply is insufficient. Therefore it is necessary to search for new technologies and alternatives to tissue banks. The bovine lyophilized xenograft (BLX) is one of these options; the production on free demand, its physical and chemical characteristics similar to human bone and its good clinical and radiological outcomes makes it a viable alternative. The aim of this study was to verify and quantify new bone formation by the histological analysis in subjects who received the BLX. This was a case series from July 2000 to April 2013 realized in the Hospital de Clínicas de Porto Alegre. This study included patients who underwent to a THARS where was used the BLX, which later was admitted to a second THARS surgery, not related to the xenograft failure but a mechanical failure of the implant. In this second surgery was performed the bone biopsy. Fourteen subjects were analyzed, 64.3% were female. The average age of patients was 52.36 ± 18.55 years. New bone formation was present in 85.7% of subjects, and constituted 61.79% of the total bone matrix. The diagnosis of BLX absorption was present in 12 subjects. A strong inverse correlation founded by the Pearson's test was observed between the proportion of new bone and the proportion of BLX (p=0.001). No inflammatory response was found. Was concluded that there was suitable bone formation in the vast majority of the cases, as well as the BLX is a good osteoconductive scaffold and can be considered an alternative to other bone graft in the treatment of bone defects.

A artroplastia é, em última análise, a opção final para o tratamento da osteoartrose. Com o aumento do número de indicações deste procedimento, a troca (artroplastia total de quadril de revisão – ATQR) dos componentes também passou a ser mais frequente. Os defeitos ósseos ou falhas ósseas são problemas que podem ser encontrados quando se realiza uma ATQR e, eles devem ser reparados, ou seja, o quadril do paciente a receber outra prótese necessita ser reconstruído. Para isto a grande maioria das técnicas empregadas requer o uso de enxerto ósseo e, devido a este motivo este tecido tem se tornado um dos tecidos mais transplantados na atualidade. Porém a demanda para utilização dos enxertos, na maioria provenientes de bancos de tecidos ósseos, tem aumentado, mas o suprimento é insuficiente. Portanto faz-se necessário a busca por novas tecnologias e alternativas aos bancos de tecidos. O enxerto bovino liofilizado (EBL) é uma destas opções, sua produção em livre demanda suas características físicas e químicas semelhantes ao osso humano e sua boa repercussão clínico-radiológica o torna uma alternativa viável. Este estudo tem o objetivo de verificar e quantificar a neoformação óssea com o uso do EBL pelo uso da avaliação histológica. Realizou-se um estudo de casos de Julho de 2000 a Abril de 2013 no Hospital de Clínicas de Porto Alegre (HCPA), onde se incluíram sujeitos que foram submetidos a uma cirurgia prévia cirurgia de ATQR onde foi utilizado o EBL os quais internaram posteriormente para uma segunda cirurgia de ATQR não relacionada a falha do enxerto e sim a falha da prótese. Nesta segunda cirurgia realizou-se a biópsia óssea. Quatorze sujeitos foram analisados, sendo 64,3% do sexo feminino. A média de idade dos pacientes foi 52,36±18,55. Neoformação óssea estava presente em 85,7% dos sujeitos, e constituiu 61,79% da área total de matriz óssea. O diagnóstico de absorção do EBL estava presente em 12 sujeitos. Uma forte correlação de proporção inversa foi constatada pelo teste de Pearson entre a porcentagem de osso neoformado e a porcentagem de EBL na área total de matriz óssea (p=0,001). Nenhuma resposta inflamatória foi encontrada. Concluiu-se que houve neoformação óssea adequada na grande maioria dos casos sendo o EBL uma boa estrutura osteocondutora, podendo ser considerado uma alternativa aos outros enxertos ósseos no tratamento das falhas ósseas. / Arthroplasty is, ultimately, the final option for the treatment of osteoarthritis. With the increasing number of indications of this procedure, the exchange (total hip arthroplasty revision surgery- THARS) also became more frequent. The bone defects are problems that can be encountered when conducting a THARS and this defect must be repaired, in other words, the patient's hip needs to be rebuilt before receive a new prosthesis. Most of techniques used to rebuild requires the use of bone graft, and because of this reason, this tissue has become one of the most transplanted tissues today. However the demand for the use of grafts, mostly from bone tissue banks, has increased, but the supply is insufficient. Therefore it is necessary to search for new technologies and alternatives to tissue banks. The bovine lyophilized xenograft (BLX) is one of these options; the production on free demand, its physical and chemical characteristics similar to human bone and its good clinical and radiological outcomes makes it a viable alternative. The aim of this study was to verify and quantify new bone formation by the histological analysis in subjects who received the BLX. This was a case series from July 2000 to April 2013 realized in the Hospital de Clínicas de Porto Alegre. This study included patients who underwent to a THARS where was used the BLX, which later was admitted to a second THARS surgery, not related to the xenograft failure but a mechanical failure of the implant. In this second surgery was performed the bone biopsy. Fourteen subjects were analyzed, 64.3% were female. The average age of patients was 52.36 ± 18.55 years. New bone formation was present in 85.7% of subjects, and constituted 61.79% of the total bone matrix. The diagnosis of BLX absorption was present in 12 subjects. A strong inverse correlation founded by the Pearson's test was observed between the proportion of new bone and the proportion of BLX (p=0.001). No inflammatory response was found. Was concluded that there was suitable bone formation in the vast majority of the cases, as well as the BLX is a good osteoconductive scaffold and can be considered an alternative to other bone graft in the treatment of bone defects.

A artroplastia é, em última análise, a opção final para o tratamento da osteoartrose. Com o aumento do número de indicações deste procedimento, a troca (artroplastia total de quadril de revisão – ATQR) dos componentes também passou a ser mais frequente. Os defeitos ósseos ou falhas ósseas são problemas que podem ser encontrados quando se realiza uma ATQR e, eles devem ser reparados, ou seja, o quadril do paciente a receber outra prótese necessita ser reconstruído. Para isto a grande maioria das técnicas empregadas requer o uso de enxerto ósseo e, devido a este motivo este tecido tem se tornado um dos tecidos mais transplantados na atualidade. Porém a demanda para utilização dos enxertos, na maioria provenientes de bancos de tecidos ósseos, tem aumentado, mas o suprimento é insuficiente. Portanto faz-se necessário a busca por novas tecnologias e alternativas aos bancos de tecidos. O enxerto bovino liofilizado (EBL) é uma destas opções, sua produção em livre demanda suas características físicas e químicas semelhantes ao osso humano e sua boa repercussão clínico-radiológica o torna uma alternativa viável. Este estudo tem o objetivo de verificar e quantificar a neoformação óssea com o uso do EBL pelo uso da avaliação histológica. Realizou-se um estudo de casos de Julho de 2000 a Abril de 2013 no Hospital de Clínicas de Porto Alegre (HCPA), onde se incluíram sujeitos que foram submetidos a uma cirurgia prévia cirurgia de ATQR onde foi utilizado o EBL os quais internaram posteriormente para uma segunda cirurgia de ATQR não relacionada a falha do enxerto e sim a falha da prótese. Nesta segunda cirurgia realizou-se a biópsia óssea. Quatorze sujeitos foram analisados, sendo 64,3% do sexo feminino. A média de idade dos pacientes foi 52,36±18,55. Neoformação óssea estava presente em 85,7% dos sujeitos, e constituiu 61,79% da área total de matriz óssea. O diagnóstico de absorção do EBL estava presente em 12 sujeitos. Uma forte correlação de proporção inversa foi constatada pelo teste de Pearson entre a porcentagem de osso neoformado e a porcentagem de EBL na área total de matriz óssea (p=0,001). Nenhuma resposta inflamatória foi encontrada. Concluiu-se que houve neoformação óssea adequada na grande maioria dos casos sendo o EBL uma boa estrutura osteocondutora, podendo ser considerado uma alternativa aos outros enxertos ósseos no tratamento das falhas ósseas. / Arthroplasty is, ultimately, the final option for the treatment of osteoarthritis. With the increasing number of indications of this procedure, the exchange (total hip arthroplasty revision surgery- THARS) also became more frequent. The bone defects are problems that can be encountered when conducting a THARS and this defect must be repaired, in other words, the patient's hip needs to be rebuilt before receive a new prosthesis. Most of techniques used to rebuild requires the use of bone graft, and because of this reason, this tissue has become one of the most transplanted tissues today. However the demand for the use of grafts, mostly from bone tissue banks, has increased, but the supply is insufficient. Therefore it is necessary to search for new technologies and alternatives to tissue banks. The bovine lyophilized xenograft (BLX) is one of these options; the production on free demand, its physical and chemical characteristics similar to human bone and its good clinical and radiological outcomes makes it a viable alternative. The aim of this study was to verify and quantify new bone formation by the histological analysis in subjects who received the BLX. This was a case series from July 2000 to April 2013 realized in the Hospital de Clínicas de Porto Alegre. This study included patients who underwent to a THARS where was used the BLX, which later was admitted to a second THARS surgery, not related to the xenograft failure but a mechanical failure of the implant. In this second surgery was performed the bone biopsy. Fourteen subjects were analyzed, 64.3% were female. The average age of patients was 52.36 ± 18.55 years. New bone formation was present in 85.7% of subjects, and constituted 61.79% of the total bone matrix. The diagnosis of BLX absorption was present in 12 subjects. A strong inverse correlation founded by the Pearson's test was observed between the proportion of new bone and the proportion of BLX (p=0.001). No inflammatory response was found. Was concluded that there was suitable bone formation in the vast majority of the cases, as well as the BLX is a good osteoconductive scaffold and can be considered an alternative to other bone graft in the treatment of bone defects.